| NCT ID | NCT04374175 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2020-04-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2020-04-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. Today, there is no any effective means of detection... Blood markers can be a simple means of early detection
Eligibility Criteria
ADENOCARCINOMA GROUP Inclusion Criteria: * Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. * At the start of treatment (before surgery / 1st course of chemotherapy) * Age ≥ 18 years * Patient affiliated or entitled to a social security system Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years * Language barrier CONTROL GROUP Inclusion Criteria: * Age ≥ 40 years * Patient affiliated or entitled to a social security system * Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease Exclusion Criteria: * Patient refusal * Acute renal failure * Child-Pugh B or C cirrhosis * Patient under guardianship or curators * Other synchronous cancer or history of cancer \<5 years
Contact & Investigator
Nicolas WILLIET, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Saint Etienne
Frequently Asked Questions
Who can join the NCT04374175 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04374175 currently recruiting?
Yes, NCT04374175 is actively recruiting participants. Contact the research team at nicolas.williet@chu-st-etienne.fr for enrollment information.
Where is the NCT04374175 trial being conducted?
This trial is being conducted at Saint-Etienne, France, Saint-Priest-en-Jarez, France.
Who is sponsoring the NCT04374175 clinical trial?
NCT04374175 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Nicolas WILLIET, MD at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 400 participants.